메뉴 건너뛰기
Journal of Inherited Metabolic Disease
Volumn 37, Issue 1, 2014, Pages 141-143
Letter to the Editors: Concerning "cRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al
Author keywords

[No Author keywords available]
Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;
EID: 84891836021     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-013-9637-8     Document Type: Letter
Times cited : (7)
References (7)
  • 1
    • 82255179514 scopus 로고    scopus 로고
    • Atypical immunologic response in a patient with CRIM-negative Pompe disease
    • 1:CAS:528:DC%2BC3MXhsFert7fI 3711241 21889385 10.1016/j.ymgme.2011.08.003
    • Abbott MA, Prater SN, Banugaria SG et al (2011) Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol Genet Metab 104:583-586
    • (2011) Mol Genet Metab , vol.104 , pp. 583-586
    • Abbott, M.A.1    Prater, S.N.2    Banugaria, S.G.3
  • 2
    • 84873548573 scopus 로고    scopus 로고
    • Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: Lessons learned from Pompe disease
    • 1:CAS:528:DC%2BC3sXit1Gktro%3D 3744338 23060045 10.1038/gim.2012.110
    • Banugaria SG, Prater SN, McGann JK et al (2013) Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 15:123-131
    • (2013) Genet Med , vol.15 , pp. 123-131
    • Banugaria, S.G.1    Prater, S.N.2    McGann, J.K.3
  • 3
    • 80051799963 scopus 로고    scopus 로고
    • The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
    • 1:CAS:528:DC%2BC3MXpvVCjurk%3D 21637107 10.1097/GIM.0b013e3182174703
    • Banugaria SG, Prater SN, Ng YK et al (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13:729-736
    • (2011) Genet Med , vol.13 , pp. 729-736
    • Banugaria, S.G.1    Prater, S.N.2    Ng, Y.K.3
  • 4
    • 71649099089 scopus 로고    scopus 로고
    • Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
    • 1:CAS:528:DC%2BD1MXhsFGgtb7I 3721340 19775921 10.1016/j.ymgme.2009.08.003
    • Kishnani PS, Goldenberg PC, DeArmey SL et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26-33
    • (2010) Mol Genet Metab , vol.99 , pp. 26-33
    • Kishnani, P.S.1    Goldenberg, P.C.2    Dearmey, S.L.3
  • 5
    • 84855542158 scopus 로고    scopus 로고
    • Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
    • 1:CAS:528:DC%2BC38Xjt1aiu7o%3D 3711224 22237443 10.1038/gim.2011.4
    • Messinger YH, Mendelsohn NJ, Rhead W et al (2012) Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14:135-142
    • (2012) Genet Med , vol.14 , pp. 135-142
    • Messinger, Y.H.1    Mendelsohn, N.J.2    Rhead, W.3
  • 6
    • 84866084747 scopus 로고    scopus 로고
    • The emerging phenotype of long-term survivors with infantile Pompe disease
    • 22538254 10.1038/gim.2012.44
    • Prater SN, Banugaria SG, DeArmey SM et al (2012) The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14:800-810
    • (2012) Genet Med , vol.14 , pp. 800-810
    • Prater, S.N.1    Banugaria, S.G.2    Dearmey, S.M.3
  • 7
    • 79952551617 scopus 로고    scopus 로고
    • CRIM-negative infantile Pompe disease: 42-month treatment outcome
    • 1:CAS:528:DC%2BC3cXhsVygsLvM 20882352 10.1007/s10545-010-9209-0
    • Rohrbach M, Klein A, Köhli-Wiesner A et al (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751-757
    • (2010) J Inherit Metab Dis , vol.33 , pp. 751-757
    • Rohrbach, M.1    Klein, A.2    Köhli-Wiesner, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.